Related Experiment Videos
Immunointervention in type 1 (insulin-dependent) diabetes mellitus
1Departement Interne Geneeskunde, AZ VUB, Brussel, België.
Acta Clinica Belgica
|January 1, 1993
Summary
Identifying autoimmune hallmarks in Type 1 diabetes can reveal the pre-clinical phase, enabling early immunotherapeutic interventions. This review discusses immunomodulation strategies for pre-diabetic individuals.
Area of Science:
- Immunology
- Endocrinology
- Autoimmunity
Background:
- Type 1 diabetes (T1D) is an autoimmune disease characterized by the destruction of pancreatic beta cells.
- The pre-clinical phase of T1D, marked by specific autoimmune markers, offers a window for intervention.
- Understanding these autoimmune hallmarks is crucial for developing early treatment strategies.
Purpose of the Study:
- To review the identified autoimmune hallmarks of Type 1 diabetes.
- To discuss their role in revealing the pre-clinical disease phase.
- To explore the potential for early immunotherapeutic approaches based on this delineation.
Main Methods:
- Literature review of autoimmune aspects in Type 1 diabetes.
- Analysis of the implication of these hallmarks in the pre-clinical phase.
- Discussion of immunomodulatory agents and their clinical trial applications.
Main Results:
- Key autoimmune markers are associated with the pre-clinical phase of Type 1 diabetes.
- Early identification of the pre-diabetic phase is possible through these hallmarks.
- Immunomodulatory agents show potential in managing or preventing disease progression.
Conclusions:
- Delineating the pre-diabetic phase through autoimmune hallmarks allows for timely immunotherapeutic interventions.
- Agents like azathioprine, cyclosporin A, and nicotinamide are being investigated for their effects in T1D.
- Targeting the pre-clinical phase holds promise for altering the natural history of Type 1 diabetes.